Predictors of glycemic control and diabetes-related costs among type 2 diabetes patients initiating therapy with liraglutide in the United States
Authors:
- 21 December 2015
- journal article
- research article
- Published by Taylor & Francis in Journal of Medical Economics
- Vol. 19 (4) , 403-413
Abstract
Objective: Liraglutide has been shown to significantly improve glycemic control and reduce body weight while minimizing the risk of hypoglycemia in adult patients with type 2 diabetes (T2D). This study aimed to identify characteristics that predict clinical and economic outcomes associated with liraglutide therapy in clinical practice in the US.Methods: Using the Truven Health MarketScan® Laboratory Database, glycemic control (A1C <7%) and diabetes-related costs were evaluated in T2D patients initiating liraglutide between 1/1/2010 and 6/30/2012. Patients were required to have ≥1 post-index claim for liraglutide and A1C values at baseline and 6 months follow-up. All valid values of baseline A1C were included. Patients previously treated with GLP-1 receptor agonist(s) or insulin, or with evidence of type 1 diabetes, pregnancy or gestational diabetes during the study period were excluded. Multivariable regression models were used to identify predictors of glycemic control and diabetes-related costs....Keywords
This publication has 20 references indexed in Scilit:
- Clinical Evidence for the Earlier Initiation of Insulin Therapy in Type 2 DiabetesDiabetes Technology & Therapeutics, 2013
- Achievement of Goals in U.S. Diabetes Care, 1999–2010New England Journal of Medicine, 2013
- The Prevalence of Meeting A1C, Blood Pressure, and LDL Goals Among People With Diabetes, 1988–2010Diabetes Care, 2013
- Metformin: an old but still the best treatment for type 2 diabetesDiabetology & Metabolic Syndrome, 2013
- LiraglutideDrugs, 2011
- Achieving a clinically relevant composite outcome of an HbA1c of <7% without weight gain or hypoglycaemia in type 2 diabetes: a meta‐analysis of the liraglutide clinical trial programmeDiabetes, Obesity and Metabolism, 2011
- Adding liraglutide to oral antidiabetic drug therapy: onset of treatment effects over timeInternational Journal Of Clinical Practice, 2009
- Adding Liraglutide to Oral Antidiabetic Drug Monotherapy: Efficacy and Weight BenefitsPostgraduate Medicine, 2009
- Randomized, Controlled Trials, Observational Studies, and the Hierarchy of Research DesignsNew England Journal of Medicine, 2000
- Adapting a clinical comorbidity index for use with ICD-9-CM administrative databasesJournal of Clinical Epidemiology, 1992